Clinical Trial Patient Technology Articles

  1. FDA Seeks Comment On Fit-For-Purpose COAs Guidance 7/14/2022

    On June 29, the FDA released the new guidance, Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. This article sums up the guidance and explains the four types of COAs that the FDA prefers (PROs, ObsROs, ClinROs, and PerfOs). Submit comments to the FDA by September 28, 2022.

  2. What Does The Future Hold For Decentralized Clinical Trials? 4/20/2022

    What can we expect to see from decentralized trials in the next three years, and what are the challenges sponsor companies will need to overcome? A webinar hosted by IBM Watson hoped to answer that question and many others.

  3. Best Practices For Designing Patient-Centric Decentralized Clinical Trials 4/12/2022

    Decentralized clinical trials are not universally applicable to all phases of a trial and therapeutic areas. The recommendations in this article may bring decentralized and hybrid trials to a more tangible and realistic view and, in essence, make them more executable.

  4. 2021 Clinical Research Site Survey Findings: A Year In Flux 3/24/2022

    Since its inception in 2012, the Society for Clinical Research Sites (SCRS) has conducted an annual survey of clinical research site community members to derive insights, reveal trends, and ensure the site perspective is represented. This article summarizes the 2021 survey's findings.

  5. When & How To Develop A Novel Digital Endpoint In Clinical Research 2/18/2022

    Many biopharma companies are leveraging digital health technologies to improve existing clinical endpoints or uncover new endpoints that could not be measured before. This article delves into the efforts being made to improve education and support the development of these novel digital endpoints as well as key considerations for pursuing one.

  6. eCOA Solution Market Outlook

    The eCOA solution market is anticipated to capture $15.1 billion by the year 2036, growing at a CAGR of almost 15.1% during the forecast period. Discover the drivers behind the growth.